Renaissance Technologies LLC Trims Stake in Kamada Ltd. $KMDA

Renaissance Technologies LLC lowered its position in Kamada Ltd. (NASDAQ:KMDA) by 9.1% in the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 762,948 shares of the biotechnology company’s stock after selling 76,350 shares during the period. Renaissance Technologies LLC’s holdings in Kamada were worth $6,363,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in KMDA. Jane Street Group LLC purchased a new stake in Kamada in the first quarter worth $582,000. Goldman Sachs Group Inc. bought a new position in Kamada in the first quarter worth $497,000. Arrowstreet Capital Limited Partnership purchased a new position in Kamada during the second quarter valued at $472,000. Bank of America Corp DE boosted its holdings in shares of Kamada by 201.0% during the 3rd quarter. Bank of America Corp DE now owns 61,565 shares of the biotechnology company’s stock valued at $427,000 after buying an additional 41,111 shares in the last quarter. Finally, Marshall Wace LLP boosted its holdings in shares of Kamada by 25.9% during the 4th quarter. Marshall Wace LLP now owns 196,954 shares of the biotechnology company’s stock valued at $1,390,000 after buying an additional 40,514 shares in the last quarter. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Kamada Trading Up 1.5%

Shares of NASDAQ:KMDA opened at $7.34 on Wednesday. The stock has a fifty day simple moving average of $7.29 and a two-hundred day simple moving average of $8.01. Kamada Ltd. has a 12-month low of $6.50 and a 12-month high of $9.35. The stock has a market capitalization of $422.12 million, a price-to-earnings ratio of 20.97, a PEG ratio of 0.66 and a beta of 0.86.

Kamada (NASDAQ:KMDA) last released its earnings results on Thursday, May 14th. The biotechnology company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.05). Kamada had a return on equity of 7.73% and a net margin of 11.21%.The company had revenue of $45.24 million during the quarter, compared to analysts’ expectations of $46.72 million. As a group, equities research analysts predict that Kamada Ltd. will post 0.44 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on KMDA shares. Benchmark reiterated a “buy” rating on shares of Kamada in a research note on Tuesday, July 21st. Weiss Ratings cut shares of Kamada from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 25th. Wall Street Zen cut shares of Kamada from a “buy” rating to a “hold” rating in a report on Saturday, May 23rd. Finally, William Blair set a $15.00 price objective on shares of Kamada in a report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $13.00.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.